The Canadian Association for Population Therapeutics/
Association Canadienne pour la Thérapeutique des Populations
Presents:

“Decisions in a Time of Change: New Frontiers in Health Policy, HTAs, and Methods”

PROGRAM

November 1st - 3rd, 2015
Toronto, Ontario
DoubleTree by Hilton
108 Chestnut Street
Toronto, Ontario
CAPT-ACTP MISSION & VISION

The CAPT-ACTP Mission is to advance population-based research of therapeutic interventions to improve the health outcomes of Canadians by:

- Bringing together diverse perspectives
- Facilitating open exchange of ideas and collaboration, and
- Influencing policy and practice

The CAPT-ACTP Vision is to become the recognized Canadian leader for linking population-based therapeutic research, policy and practice to optimize health outcomes.

www.capt-actp.com
CAPT-ACTP 2015 BOARD OF DIRECTORS:
Allan Gillman  CAPT-ACTP President, IMS Brogan Inc.
Nicole Mittmann  CAPT-ACTP Past President, Cancer Care Ontario
Judith Glennie  CAPT-ACTP President Elect, J.L. Glennie Consulting Inc.
Colleen Metge  CAPT-ACTP Treasurer, Centre for Healthcare Innovation, University of Manitoba
Peggy Kee  CAPT-ACTP Administrator, HOPE Research Centre, Sunnybrook Research Institute

Members at Large
Mary De Vera  Faculty of Pharmaceutical Sciences, University of British Columbia
Alice Dragomir  McGill University
Peter Dyrda  Janssen Inc.
Dean Eurich  School of Public Health, University of Alberta
Diane Forbes  Canadian Institutes of Health Research
Naeem Ladhani  Alberta Health Services
Laurene Redding  Takeda Canada Inc.
Soo Jin Seung  HOPE Research Centre, Sunnybrook Research Institute
Melissa Thompson  Cornerstone Research Group
Nicole Tsao  University of British Columbia

CAPT-ACTP 2015 SCIENTIFIC PROGRAM COMMITTEE:
Chair:  Dean Eurich
Members:  Alice Dragomir
          Mary De Vera
          Judith Glennie
          Johnny Ma
          Melissa Thompson

CAPT-ACTP 2015 LOCAL ORGANIZING COMMITTEE:
Chair:  Soo Jin Seung
Members:  Shazia Hassan
          Peggy Kee

CAPT-ACTP 2015 MEMBERSHIP & MARKETING COMMITTEE:
Chairs:  Naeem Ladhani & Peter Dyrda
Members:  Judith Glennie
          Diane Forbes

CAPT-ACTP 2015 PARTNERSHIP COMMITTEE:
Chairs:  Nicole Mittmann & Laurene Redding
Members:  Karen Agro
          Kimberly Robinson

CAPT-ACTP 2015 STUDENT COMMITTEE:
Chairs:  Nicole Tsao & Mary De Vera

CAPT-ACTP 2015 FINANCE COMMITTEE:
Chair:  Colleen Metge
Decisions in a Time of Change: New Frontiers in Health Policy, HTAs, and Methods”

Message from the President

It is my pleasure to welcome you to the 2015 Canadian Association for Population Therapeutics (CAPT)/ Association Canadienne pour la Thérapeutique des Populations (ACTP) annual conference! CAPT/ACTP brings together the perspectives of academia, industry, government, and private payers, in an intimate and collegial conference designed to challenge our speakers, engage its members, and provide an opportunity for innovative and interesting ideas to percolate.

Your input has been instrumental in shaping the content this year and this is reflected in the conference theme “Decisions in a Time of Change: New Frontiers in Health Policy, HTAs, and Methods”. Our Scientific Program Committee has been hard at work tapping into the topics and themes that you indicated were important, and that has allowed us to explore topical subjects from rare diseases, medical devices, affordability, value frameworks, and national pharmacare, to mainstays of HTA, and advanced methods.

As always we have a full slate of panels, oral presentations, posters, and a methods workshop for you to enjoy. We are particularly proud of our support of student engagement at the conference in oral presentations, posters, mentoring and social events. So take advantage of the many opportunities you will have to engage with others at the conference and participate as much as you can!
As usual, the scientific program committee, the local organizing committee, and our partnership committees have done an incredible job in making sure that everything comes together in what you'll see over the duration of the conference. I want to thank them, our speakers, participants, and partners for contributing to our ongoing success. Please let us know what we can do better, spread the word, and consider becoming more actively involved! Most of all...enjoy!

Allan F. Gillman
CAPT-ACTP President
CAPT-ACTP 2015 Conference Overview

The theme of this year’s conference is ‘Decisions in a Time of Change: New Frontiers in Health Policy, HTAs, and Methods’ which speaks to the changing landscape of the Canadian health care environment and the increasing role of HTA and methods in the decision process. The title also speaks to some of health discussions that are also occurring in the country around major policy issues impacting Canadians. Major subthemes identified by the Scientific Committee include:

a) Innovative tools and methods to inform decision making  
b) Impact of the environment on the health care system  
c) National Pharmacare and other emerging health policy issues

CAPT-ACTP’s mission is to bring together stakeholders from diverse perspectives for scientific and policy exchange, and to dialogue on hot topics in health care practice. This year’s meeting continues to draw on the collective wisdom of all our constituencies, including academia, industry, government and trainees.

With our pre-conference workshop/symposium, panel discussions, abstract presentations and ongoing collaboration with the CIHR/DSEN Program the 2015 CAPT-ACTP meeting promises to have something for everyone!

Dean Eurich  
CAPT-ACTP Scientific Program Committee Chair
Background/Rationale:
Population-based studies of comparative effectiveness and safety of drugs typically rely on large administrative health databases, which do not record information on clinical and lifestyle characteristics, or laboratory tests. Yet, some of these un-measured variables likely affect both the treatment choice and the outcome of interest, raising concerns about un-measured confounding.

Objectives:
Our workshop will help update the participants on recent advances in methodological research which focus on eliminating or reducing bias due to un-measured confounding. Although no ‘panaceum’, able to provide a general solution to this complex problem, can be envisaged, some promising methods have been recently proposed, and validated, to address un-measured confounding in various situations, relevant for a substantial proportion of real-life observational studies.

Outline of the content:
Individual speakers will discuss the concepts and the conditions, under which different, recently proposed, methods, can be applied and explain how the results can be interpreted. Some know-how regarding the implementation of specific methods will be also outlined. Each method will be illustrated with an example of a real-life drug safety or effectiveness study.

All talks will be at the level appropriate for researchers and trainees in epidemiology, public health and related areas, who have taken courses in epidemiology, applied statistics or biostatistics. (“Technical” details, mathematical proofs will be avoided and only a few, basic equations (if any) will be presented.) Focus will be on concepts, assumptions, practical aspects of use of the methods, and interpretation of the results.
Monday, November 2, 2015

07:00 – 08:00  Registration / Breakfast *(sponsor: GlaxoSmithKline Inc.)*  
Location: Mandarin Ballroom Foyer

08:00 – 08:15  Welcome to Day 1  
Location: Mandarin Ballroom  
Presenter: Allan Gillman, IMS Brogan Inc.

08:15 – 09:45  Panel Session: Rare Diseases: What Does the Future Hold?  
Location: Mandarin Ballroom  
Chair: Judith Glennie, J.L. Glennie Consulting Inc.  
Speakers: Fred Horne, Horne and Associates; Adjunct Professor, School of Public Health, University of Alberta; former Minister of Health, Alberta, Zayna Khayat, MaRS EXCITE; and Health Lead - MaRS Discovery District Wayne Critchley, Health & Life Sciences, Global Public Affairs; and Board member, Canadian Organization for Rare Diseases (CORD)

**Overview:** The objective of this session will be to discuss the latest developments in health policy, HTA, and methods related to rare disease products and to gain an understanding of the issues that are likely to drive future changes to the way we manage rare disease products.

09:45 – 10:15  Nutrition Break

10:15 – 11:15  Interactive Session: Medical Devices  
Location: Mandarin Ballroom  
Chair: Nicole Mittmann, Cancer Care Ontario  
Speakers: Murray Krahn, THETA and Ontario Health Technology Assessment Committee Howard Rosen, LifeWIRE Corp Hamid Sadri, Medtronic

**Overview:** The objective of this session will be to discuss issues related to the development, assessment, and reimbursement of devices and/or technologies to optimize patient outcomes and provide the best value for money.

11:15 – 12:15  Lunch *(sponsor: Hoffmann-La Roche Ltd.)*  
Location: Mandarin Ballroom

11:30 – 12:15  Student Mentoring Session / CV Building (open to CAPT-ACTP student registrants only)  
Location: Toronto Ballroom  
Chair: Nicole Tsao, Student Committee Chair CAPT-ACTP.

**Overview:** The session will allow students to network with CAPT-ACTP members. These sessions introduce students to different work environments. The meetings will emphasize strategies for finding a workplace position and CV review.
Location: Mandarin Ballroom
Chair: Don Husereau, Institute of Health Economics
Speakers: Chad Mitchell, Pharmaceutical Strategy and Foresight, Alberta Health
Michael Tremblay, Astellas Pharma Canada, Inc.
Brent Fraser, Pharmaceutical Reviews, CADTH
Brad Alyward, Nova Scotia Department of Health and Wellness

**Overview:** The Canadian drug reimbursement landscape is in a state of evolution leaving stakeholders striving to adapt to the environment while delivering safe and effective medications to Canadians. In recent years a growth of initiatives aimed at controlling drug costs has paralleled the increasing rate of advancements in drug development. The continued development of these initiatives such as the pan-Canadian Pharmaceutical Alliance (pCPA) and a variety of individual provincial policies suggest that funding decisions being made today are occurring in a new affordability frontier. As these initiatives become a more integral piece of the puzzle in the bench-to-bedside transition, is it time to re-assess how the dots are connected between health technology assessment (HTA) and drug funding decision? Are current HTA processes aligned with how funding decisions are being made and if not what modifications could/should be made? Are there best practices we can take away from systems in other countries?

13:45 – 14:15  Nutritional Break

14:15 – 15:45  Drug Safety and Effectiveness Network: Methods to Madness
Location: Mandarin Ballroom
Chair: Diane Forbes, Canadian Institutes of Health Research
Speakers: Michal Abrahamowicz, McGill University
Robert Platt, McGill University
Brian Hutton, University of Ottawa
Robert Peterson, Drug Safety and Effectiveness Network

**Overview:** The objective of this session is to provide a learning-focused session to allow the audience to increase their familiarity with advanced methods in pharmacoepidemiology. Participants should come away from the session with an increased confidence in: i) Approaching a gap in knowledge in the evidence base underlying a problem faced in the real world; ii) Identifying the potential sources of bias to be addressed in the context of research on a particular question and iii) Understanding the strengths and considerations in applying advanced methods to that question.

15:45 – 16:45  Unconference Conference
Location: Mandarin Ballroom
Chair: Colleen Metge, Centre for Healthcare Innovation, University of Manitoba
Speakers: CAPT membership

**Overview:** The objective of this session will be to discuss important issues highlighted in the previous talks. Government, industry and academic CAPT-ACTP membership will have the ability to identify and discuss burning questions about policy, decision-making, methodologies and strategies for drugs and technologies.

16:45 – 17:00  Day 1 Summary Comments
Location: Mandarin Ballroom
Presenter: Allan Gillman, President CAPT-ACTP, IMS Brogan Inc.
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 17:00 – 19:00 | Contributed Poster Presentation Session and Reception  
(Sponsor:AstraZeneca Canada Inc.)  
Location: Toronto Ballroom |
| 19:30  | Student Social Event                         |
Tuesday, November 3, 2015

07:00 – 08:00  Registration / Breakfast *(sponsor: IMS Brogan Inc.)*  
Location: Mandarin Ballroom Foyer

08:00 – 08:15  Welcome to Day 2  
Location: Mandarin Ballroom  
Presenter: Allan Gillman, IMS Brogan Inc.

08:15 – 09:45  Panel Session: Shaping a Value Framework for Immuno-Oncology: Hopes and Fears  
Location: Mandarin Ballroom  
Chair: Judith Glennie, President – J.L. Glennie Consulting Inc.  
Speaker Barry Stein, Colorectal Cancer Association of Canada  
Dr. Brett J. Skinner Canadian Health Policy Institute; Health and Economic Policy at Canada's Research-Based Pharmaceutical Companies (Rx&D)  
Dr. William K. (Bill) Evans, McMaster Univ., Department of Medical Oncology  
Dr. Eric Chen, Princess Margaret Cancer Centre  
Dr. Yoo-Joung (Yooj) Ko, Sunnybrook Health Sciences Centre

**Overview:** To provide an overview of emerging immune therapies in oncology, and to discuss how they are changing cancer treatment paradigms. Discuss challenges and opportunities in evaluating these new oncologic products from different perspectives, and how to incorporate these values and perspectives in effective HTA and reimbursement decision-making processes.

09:45 – 10:15  Nutritional Break

10:15 – 11:15  Contributed Oral Presentations – Concurrent Sessions  
10 presentations  
Location: Mandarin Ballroom A  
Chair: Colleen Metge, Centre for Healthcare Innovation, University of Manitoba

1. The premarket assessment of the cost-effectiveness of a predictive technology StraticyteTM for the early detection of oral cancer  
*Shoghag Khoudigian*

2. The effect of Functional Electrical Stimulation (FES) on improving upper limb function in stroke patients: A systematic review and meta-analysis of randomized controlled trials  
*Kimberly Castellano*

*Scott Gavura*

4. Employment status and mobility before and after bariatric surgery: a one-year prospective sub-study of the Ontario bariatric registry  
*Jean-Eric Tarride*
5. Costs for childhood cancer, pre-diagnosis and 1-year post-diagnosis: a population-based study in Ontario

*Karen E Bremner*

**Concurrent Session 2**

Location: Mandarin Ballroom B  
Chair: Soo Jin Seung, HOPE Research Centre, Sunnybrook Research Institute

1. Cost effectiveness study on the use of abiraterone in the management of castration-resistant prostate cancer in real-life setting in Quebec

*Joice Rocha*

2. Castration-Resistant Prostate Cancer (CRPC): evaluation of the quality of care and disease management in real-life setting

*Halima Lahcene*

3. Impact of initial primary treatment on late regional complications in castration-resistant prostate cancer patients in Quebec

*Jason Hu*

4. New drugs for rare disorders: is Canada still condemning sufferers?

*Nigel Rawson*

5. Castration-resistant prostate cancer patients in Quebec: Medication use in the last year of life

*Alice Dragomir*

**11:15 – 12:45**  
**Lunch & Annual General Meeting** *(sponsor: Takeda Canada Inc.)*

Location: Mandarin Ballroom

**12:45 – 14:15**  
**Panel Session: Evolving the Collaboration between Regulatory and Health Technology Assessment Agencies**

Location: Mandarin Ballroom  
Chair: Rebecca Yu, Janssen Inc. (moderator)  
Speakers: Vratislav Hadrava, Pfizer Canada Inc  
Judith Glennie, President – J.L. Glennie Consulting Inc.  
Brent Fraser, Pharmaceutical Reviews, CADTH

**Overview:** In Canada, as well as in many other countries, there exist independent national bodies which complete regulatory reviews and health technology assessments. These multiple reviews, often of the same data, creates delays between a product receiving marketing authorization for use and a product being reimbursed or included on formularies. This symposium will discuss the role of each body and the evolution which has begun to take place whereby regulatory and HTA bodies have begun to work collaboratively

**14:15 – 14:45**  
**Nutritional Break**
14:45 – 16:15  **Panel Session: National Pharmacare**
Location: Mandarin Ballroom
Chair: Chris Bonnett, Manulife (moderator)
Speakers: Fred Horne, Horne and Associates; School of Public Health, University of Alberta; former Minister of Health, Alberta
Steve Morgan, University of British Columbia
Steve Sampson, Health & Life Sciences at Global Public Affairs
Louise Binder, Health Policy Consultant
Stephen Frank, Canadian Life and Health Insurance Association

**Overview:** This will be a multi-stakeholder panel discussion on National Pharmacare. Stakeholders will present and discuss their vision of National Pharmacare, its pros and cons, and any significant impediments or concerns.

16:15 – 16:30  **CAPT-ACTP Awards Ceremony / Closing Remarks**
Location: Mandarin Ballroom
Presenter: Allan Gillman, CAPT-ACTP President, IMS Brogan Inc.

For any inquiries: (abstracts, hotel, registration, etc.) please contact Ms. Peggy Kee (peggy.kee@sunnybrook.ca) or visit the CAPT-ACTP website (www.capt-actp.com).
2015 CAPT-ACTP CONFERENCE PARTNERS

**PLATINUM**
CIHR / DSEN / CNODES
Janssen Inc.
Merck & Co., Canada Inc.
Pfizer Canada Inc.

**GOLD**
AstraZeneca Canada Inc.

**SILVER**
GlaxoSmithKline Inc.
Hoffmann-La Roche Ltd.
IMS Brogan Inc.
Takeda Canada Inc.

**BRONZE**
Amgen Canada Inc.
Athena Research
Cornerstone-Research Group
HOPE Research Centre
J.L. Glennie Consulting Inc.
Mapol Inc.

**Media Sponsor**
Longwoods Publishing Co.
We gratefully acknowledge sponsorship of the 2015 CAPT-ACTP Conference by the following donors:

PLATINUM

GOLD

SILVER

BRONZE

MEDIA SPONSOR

J.L. Glennie Consulting Inc.